Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant asparaginase in infants with newly diagnosed acute lymphoblastic leukemia
NL-OMON33689Phase 2Active, not recruiting
- Sponsor
- medac GmbH
- Start
- Oct 2009
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of asparaginase escherichia coli in acute lymphoblastic leukemia (ALL), sponsored by medac GmbH. Primary endpoint: Hypersensitivity reactions. Started Oct 2009; status: active, not recruiting.
02
Drugs
asparaginase escherichia coli
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON33689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33689.